BRD4-targeted therapy ABBV-744 clinical data No Further a Mystery
In Phase C, contributors will get ABBV-744 and oral navitoclax. In Segment D, individuals will acquire ABBV-744 and ruxolitinib. Participants will get treatment until eventually ailment progression or the individuals are unable to tolerate the study drugs.There may be bigger treatment burden for contributors On this trial compared to their common o